VIJAYA - Vijaya Diagnost.
📢 Recent Corporate Announcements
Vijaya Diagnostic Centre Limited has scheduled a virtual group meeting with institutional investors and analysts from Goldman Sachs India's Healthcare Services Tour. The meeting is set for March 17, 2026, between 09:30 A.M. and 10:30 A.M. IST. The company clarified that discussions will be restricted to publicly available information, ensuring no unpublished price sensitive information is disclosed. This interaction highlights the company's ongoing engagement with major institutional investors to discuss business outlook.
- Meeting scheduled for March 17, 2026, from 09:30 A.M. to 10:30 A.M. IST
- Interaction with Goldman Sachs India, Healthcare Services Tour
- The meeting will be conducted in a virtual group format
- Discussions will focus strictly on publicly available information
Vijaya Diagnostic reported its highest-ever quarterly revenue of ₹205 crores in Q3 FY26, marking a robust 21.4% YoY growth driven by a 14.7% increase in test volumes. Profitability showed significant improvement with EBITDA rising 28.2% YoY to ₹86 crores, while EBITDA margins expanded by 221 basis points to reach 41.9%. The company successfully expanded its footprint with four new hubs during the quarter, including two in West Bengal where early launches have already achieved breakeven within three quarters. Management maintains a strong balance sheet with a net surplus cash of ₹260 crores and has planned a capex of ₹100-120 crores for FY27 to fuel further expansion.
- Highest ever quarterly revenue of ₹205 crores, up 21.4% YoY with 14.7% volume growth
- EBITDA margins expanded by 221 bps YoY to 41.9%, with PAT growing 22.3% to ₹43 crores
- Core Hyderabad market grew 15% YoY, while West Bengal expansion showed early success with 3-quarter breakevens
- Strong liquidity position with net surplus cash of ₹260 crores as of December 31, 2025
- Planned FY27 capex of ₹100-120 crores focusing on 4-5 new hubs and 10-12 spokes
Vijaya Diagnostic Centre Limited has officially released the audio recording of its earnings conference call held on February 13, 2026. The call followed the announcement of the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. This disclosure is part of the company's regulatory compliance and provides transparency regarding management's discussion on financial performance. Investors can access the recording via the company's website to understand the underlying business drivers for the quarter.
- Audio recording of the Q3 FY2026 earnings conference call is now available for public access.
- The conference call was conducted on February 13, 2026, following the Q3 results declaration.
- Covers financial and operational performance for the nine-month period ending December 31, 2025.
- The recording is hosted on the company's official investor relations portal and external links.
- Provides a platform for management to address analyst queries regarding the diagnostic sector's outlook.
Vijaya Diagnostic Centre has announced a major leadership restructuring, appointing Mr. Ankit Shah as the new Chief Financial Officer effective February 13, 2026. The company also strengthened its executive team by appointing Mr. Sai Prasad as CTO and Mr. Venkata Siva Rama Raju Vegesna as COO to drive digital and operational growth. Additionally, the board approved the grant of 1,15,000 ESOPs and the appointment of two new Independent Directors for five-year terms. The outgoing CFO, Mr. S. Ramachandra Reddy, will transition to a General Manager role within the finance department.
- Mr. Ankit Shah appointed as CFO, bringing 20+ years of experience in healthcare finance and M&A.
- New CTO and COO roles filled to lead digital transformation and operational strategy.
- Grant of 1,15,000 ESOPs approved under the VDCL Employee Stock Option Plan 2018.
- Two Independent Directors appointed for 5-year terms, strengthening board governance.
- Outgoing CFO Mr. S. Ramachandra Reddy remains with the company as GM - Finance & Accounts.
Vijaya Diagnostic Centre has announced a major leadership restructuring effective February 13, 2026, to strengthen its executive team. Mr. Ankit Shah, a Chartered Accountant with over 20 years of experience, has been appointed as the new CFO, replacing Mr. S. Ramachandra Reddy who transitions to a General Manager role. The company also appointed Mr. Venkata Siva Rama Raju Vegesna as COO and Mr. Sai Prasad as CTO to lead operations and digital transformation. Additionally, the board approved the grant of 1,15,000 ESOPs and inducted two new Independent Directors with legal and medical expertise.
- Appointment of Mr. Ankit Shah as CFO, bringing 20+ years of experience in healthcare finance and M&A.
- Mr. Venkata Siva Rama Raju Vegesna joins as COO, previously serving as SVP Operations at KIMS Hospitals.
- Mr. Sai Prasad appointed as CTO to drive large-scale digital transformation and IT strategy.
- Grant of 1,15,000 Employee Stock Options (ESOPs) approved under the 2018 plan.
- Induction of two new Independent Directors: Senior Advocate Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola.
Vijaya Diagnostic Centre has announced a major management restructuring, appointing Ankit Shah as the new Chief Financial Officer, succeeding S. Ramachandra Reddy who transitions to a General Manager role. The company also strengthened its executive team by appointing Sai Prasad as Chief Technology Officer and Venkata Siva Rama Raju Vegesna as Chief Operating Officer. Furthermore, two Independent Directors with legal and medical expertise have been added to the board for five-year terms. To align interests, the board approved the grant of 1,15,000 ESOPs under the company's 2018 incentive plan.
- Ankit Shah appointed as CFO, bringing over 20 years of experience in healthcare finance and M&A.
- Venkata Siva Rama Raju Vegesna returns to the company as COO after a stint at KIMS Hospitals.
- Sai Prasad joins as CTO to lead digital transformation, previously serving as Director at UnitedHealth Group.
- Board approved the grant of 1,15,000 ESOPs convertible into equity shares of face value ₹1 each.
- Two new Independent Directors, Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, appointed for 5-year terms.
Vijaya Diagnostic Centre has announced a significant leadership restructuring, appointing Mr. Ankit Shah as the new CFO, replacing Mr. S. Ramachandra Reddy who will transition to a General Manager role. The company also strengthened its executive team by appointing Mr. Sai Prasad as CTO and Mr. Venkata Siva Rama Raju Vegesna as COO, both bringing extensive experience from the healthcare and technology sectors. Additionally, two new Independent Directors have been appointed for five-year terms, and the board approved the grant of 1,15,000 ESOPs to employees. These moves appear aimed at professionalizing management and driving digital and operational growth.
- Appointment of Mr. Ankit Shah as CFO, bringing 20+ years of experience in healthcare finance and M&A.
- New CTO Mr. Sai Prasad and COO Mr. Venkata Siva Rama Raju Vegesna join to lead digital and operational strategies.
- Grant of 1,15,000 Employee Stock Options (ESOPs) approved under the 2018 plan.
- Two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, appointed for 5-year terms.
- Former CFO Mr. S. Ramachandra Reddy transitions to General Manager - Finance & Accounts to support the transition.
Vijaya Diagnostic Centre has announced a significant leadership restructuring, including the appointment of a new CFO (Ankit Shah), COO (Venkata Siva Rama Raju Vegesna), and CTO (Sai Prasad). The board also approved the grant of 1,15,000 ESOPs under its 2018 plan, which are convertible into an equivalent number of equity shares. Alongside these executive changes, two new Independent Directors with legal and medical expertise have been appointed for five-year terms. These announcements were made following the board's approval of the Q3 and nine-month financial results for FY26.
- Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value each.
- Appointment of Ankit Shah as Chief Financial Officer, succeeding S. Ramachandra Reddy who moves to a GM role.
- Venkata Siva Rama Raju Vegesna appointed as COO, bringing experience from KIMS Hospitals and previous tenure at Vijaya.
- Appointment of two new Independent Directors, Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
- New Chief Technology Officer (Sai Prasad) appointed to lead digital transformation and IT strategy.
Vijaya Diagnostic reported a strong Q3 FY26 with revenue growing 21.4% YoY to INR 2,052 Mn, driven by a 14.7% increase in test volumes. EBITDA margins expanded by 221 bps YoY to 41.9%, resulting in an EBITDA of INR 861 Mn. The company successfully commissioned four new hub centers during the quarter, expanding its footprint in West Bengal and its core markets. Net profit (PAT) rose 22.3% YoY to INR 432 Mn, maintaining a healthy 21% margin despite seasonal softness.
- Revenue from operations grew 21.4% YoY to INR 2,052 Mn in Q3 FY26
- EBITDA increased by 28.2% YoY to INR 861 Mn, with margins improving to 41.9% from 39.7%
- Test volumes rose 14.7% YoY to 4.22 Mn, while footfalls increased 11.8% to 1.17 Mn
- Network expanded to 162 centers with 4 new hubs launched in West Bengal, Telangana, and Andhra Pradesh
- B2C segment remains the core focus, contributing 92% of total revenue
Vijaya Diagnostic reported a strong Q3 FY26 with revenue growing 21.4% YoY to ₹2,052.1 million, driven by a 14.7% increase in test volumes. Profitability improved significantly as EBITDA rose 28.2% YoY, leading to a margin expansion of 221 bps to 41.9%. The company successfully expanded its footprint in West Bengal and core markets, with new hubs breaking even faster than expected. Management's focus on high-end radiology and wellness (14.7% share) continues to drive realization per footfall higher by 8.6%.
- Revenue from operations grew 21.4% YoY to ₹2,052.1 Mn, surpassing Q2 levels despite seasonal softness.
- EBITDA margins expanded by 221 bps YoY to 41.9%, while PAT increased 22.3% to ₹431.8 Mn.
- Operational efficiency improved with average realization per footfall up 8.6% YoY to ₹1,756.
- Rapid expansion in West Bengal with two hubs breaking even within 3 quarters, well ahead of the 1-year guidance.
- Total test volume increased by 14.7% YoY to 4.22 million, supported by an 11.8% growth in footfall.
Vijaya Diagnostic Centre has undergone a significant leadership restructuring, appointing a new CFO, CTO, and COO effective February 13, 2026. Mr. Ankit Shah succeeds Mr. S. Ramachandra Reddy as CFO, while the company also added two new Independent Directors to its board for five-year terms. The board approved the financial results for the quarter ended December 31, 2025, and authorized the grant of 1,15,000 ESOPs. Additionally, the company's Related Party Transaction policy was revised to enhance governance.
- Appointment of Mr. Ankit Shah as CFO and Mr. Venkata Siva Rama Raju Vegesna as COO.
- Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value.
- Appointment of two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
- Mr. S. Ramachandra Reddy resigned as CFO to transition into a General Manager role within the company.
- Approval of Unaudited Standalone and Consolidated Financial Results for Q3 and 9M ended December 31, 2025.
Vijaya Diagnostic Centre has announced a significant leadership restructuring, appointing Ankit Shah as the new Chief Financial Officer following the resignation of S. Ramachandra Reddy. The company also strengthened its executive team by appointing Sai Prasad as CTO and Venkata Siva Rama Raju Vegesna as COO, the latter returning from KIMS Hospitals. Additionally, the board approved the grant of 1,15,000 ESOPs to employees and inducted two new Independent Directors with legal and medical expertise. These changes appear aimed at modernizing operations and scaling the business through specialized leadership.
- Appointment of Ankit Shah as CFO, a Chartered Accountant with 20+ years of experience in healthcare finance.
- Venkata Siva Rama Raju Vegesna appointed as COO, bringing back expertise from his previous tenure at Vijaya and KIMS Hospitals.
- Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value.
- Appointment of Sai Prasad as CTO to lead digital transformation, previously Director at UnitedHealth Group.
- Induction of two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
Vijaya Diagnostic Centre Limited has scheduled an earnings conference call for Friday, February 13, 2026, at 5:00 PM IST. The management will discuss the company's financial performance for the third quarter and the nine-month period ended December 31, 2025. Key participants include the Managing Director & CEO, Suprita Reddy, and the CFO. This call is a standard procedure following the release of quarterly financial results to provide clarity on operational metrics.
- Earnings conference call scheduled for February 13, 2026, at 05:00 P.M. IST.
- Discussion will focus on Q3 FY26 and 9M FY26 financial results ending December 31, 2025.
- Top management including MD & CEO Suprita Reddy and the CFO will be present.
- Call hosted by JM Financial Institutional Securities Limited with universal dial-in +91-22-6280 1366.
- International toll-free numbers provided for USA, UK, Singapore, and Hong Kong investors.
Vijaya Diagnostic Centre Limited has announced its participation in two major institutional investor conferences in Mumbai. The company will attend the Kotak Institutional Equities 'Chasing Growth 2026' event on February 25, 2026, followed by IIFL’s 17th Enterprising India Global Investors’ Conference on February 26, 2026. Both events involve group and one-on-one meetings scheduled from 9:00 AM to 5:00 PM IST. The company has stated that no unpublished price sensitive information will be shared during these interactions.
- Meeting with Kotak Institutional Equities scheduled for February 25, 2026, in Mumbai.
- Participation in IIFL’s 17th Enterprising India Global Investors’ Conference on February 26, 2026.
- Interaction sessions are scheduled between 09:00 A.M. and 05:00 P.M. IST on both days.
- Format includes both Group and One-on-One in-person meetings.
- Discussions will be strictly limited to publicly available information.
Vijaya Diagnostic Centre Limited has completed the allotment of 1,71,792 equity shares to the shareholders of Medinova Diagnostic Services Limited. This procedural step follows the NCLT-approved Scheme of Amalgamation, with the record date previously fixed as November 25, 2025. Consequently, the company's paid-up equity share capital has increased from approximately ₹10.27 crore to ₹10.29 crore. Fractional entitlements will be managed by an independent trustee, who will sell the consolidated shares and distribute the proceeds to eligible shareholders.
- Allotment of 1,71,792 equity shares of face value ₹1 each to Medinova shareholders.
- Total paid-up equity share capital increased from ₹10,26,87,111 to ₹10,28,96,728.
- The allotment is pursuant to the NCLT Hyderabad Bench order dated October 13, 2025.
- Fractional entitlements consolidated and allotted to Catalyst Trusteeship Limited for open market disposal.
- Shares will rank pari-passu with existing equity and will be listed on both NSE and BSE.
Financial Performance
Revenue Growth by Segment
Consolidated revenue for Q2 FY26 reached INR 202 Cr, representing a 10.2% YoY growth and a 7.2% QoQ increase. For H1 FY26, revenue stood at INR 390 Cr, a 15% YoY growth. This growth is primarily driven by an 8.3% YoY increase in test volumes. Segment-specific percentage splits for pathology vs radiology were not disclosed in the provided documents.
Geographic Revenue Split
The company is heavily concentrated in South India, with significant expansion in Pune and Bengaluru. In Q2 FY26, revenue in Pune saw a decline despite the addition of 4 new centers. Conversely, the Yelahanka Hub in Bengaluru achieved break-even within 2 quarters, significantly ahead of the 1-year projection, contributing to regional growth.
Profitability Margins
The company maintains high profitability with a PAT margin of 21.5% in Q2 FY26 (INR 43.4 Cr) and 21% for H1 FY26 (INR 82 Cr). These healthy margins are sustained by the efficient ramp-up of new hub centers which reduces the operational drag typically associated with new facility launches.
EBITDA Margin
EBITDA margin for Q2 FY26 was 40.6%, and H1 FY26 EBITDA stood at INR 155 Cr with a 40% margin. This exceeds the management's full-year guidance of 38-39%. The margin strength is attributed to the resilience of the business model and the faster-than-expected break-even of the Yelahanka hub center.
Capital Expenditure
While specific total CAPEX for FY26 was not disclosed, the company is actively investing in expansion, having added 4 centers in Pune and a major hub in Bengaluru. The Medinova Diagnostic Services Limited merger (effective April 1, 2024) represents a significant capital allocation toward inorganic growth.
Credit Rating & Borrowing
As of April 30, 2025, CRISIL reaffirmed ratings of 'CRISIL B+/Stable/CRISIL A4' for INR 40 Cr of bank loan facilities. The rating is classified as 'Issuer Not Cooperating' because the company did not provide the required information for a full review, which may impact future borrowing costs.
Operational Drivers
Raw Materials
Not disclosed in available documents. Diagnostic companies typically use reagents, chemicals, and medical consumables.
Capacity Expansion
The company is expanding its hub-and-spoke model. Recent expansions include 4 new centers in Pune and the Yelahanka Hub in Bengaluru. The merger with Medinova Diagnostic Services Limited (approved Oct 2025) will further expand the network capacity.
Raw Material Costs
Not disclosed in available documents; however, the company reported a 'minimal drag' from new centers, suggesting efficient management of consumables and operational costs.
Manufacturing Efficiency
Efficiency is measured by the break-even timeline of new hubs. The Yelahanka hub achieved break-even in 2 quarters (50% faster than the 4-quarter projection), indicating high operational efficiency in new market entries.
Logistics & Distribution
The company utilizes a hub-and-spoke model where samples are collected at smaller centers and transported to larger hubs for testing. Distribution costs are managed through this centralized processing strategy.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
The 15% CAGR will be achieved through a combination of volume growth (8.3% YoY currently), the expansion of hub centers in new geographies like Pune and Bengaluru, and inorganic growth via the Medinova merger. Management focuses on achieving break-even for new centers within 6-12 months to maintain consolidated margins.
Products & Services
Comprehensive diagnostic medicare services including pathology tests, radiology (MRI, CT scans), and integrated health check-up packages.
Brand Portfolio
Vijaya Diagnostic Centre, Medinova Diagnostic Services (post-merger).
New Products/Services
Expansion of high-end radiology services in new hub centers; expected to contribute to the 15% top-line growth guidance.
Market Expansion
Targeting deeper penetration in Pune and Bengaluru. The company is also integrating Medinova's existing network into its operations following NCLT approval in October 2025.
Market Share & Ranking
Not disclosed in available documents, though described as a 'leading diagnostic medicare' provider.
Strategic Alliances
Merger with Medinova Diagnostic Services Limited, effective April 1, 2024, to consolidate market position in the diagnostic sector.
External Factors
Industry Trends
The diagnostic industry is shifting toward organized players and hub-and-spoke models to improve margins. Vijaya is positioning itself by launching large-scale hubs that offer both pathology and radiology, creating a 'one-stop' service moat.
Competitive Landscape
The industry is competitive with both national chains and local labs. Vijaya's recent revenue dip in Pune despite center additions highlights the intense competitive pressure in new markets.
Competitive Moat
Vijaya's moat is built on its integrated 'Pathology + Radiology' model and brand reputation. This is sustainable because radiology requires high CAPEX, creating a barrier to entry for smaller pathology-only labs. The 40% EBITDA margin reflects this competitive advantage.
Macro Economic Sensitivity
The business is sensitive to healthcare spending and seasonal disease cycles. Management notes that performance should be viewed at a 'year level' rather than quarterly due to these sensitivities.
Consumer Behavior
There is an increasing trend toward preventive health check-ups and a preference for branded diagnostic centers that offer comprehensive services under one roof.
Regulatory & Governance
Industry Regulations
Operations are subject to healthcare diagnostic standards and NCLT regulations for corporate restructuring (as seen in the Medinova merger approval).
Taxation Policy Impact
The company paid a final dividend of INR 2 (200%) per share for FY25, reflecting a policy of returning value to shareholders while maintaining growth capital.
Legal Contingencies
The company successfully navigated the NCLT approval process for the Medinova merger in October 2025. No other major pending court cases or labor disputes were detailed in the provided snippets.
Risk Analysis
Key Uncertainties
The primary uncertainty is the 'Issuer Not Cooperating' status with CRISIL, which could impact credit access. Additionally, the 10.2% revenue growth in Q2 is lower than the 15% CAGR guidance, creating pressure to perform in H2.
Geographic Concentration Risk
High concentration in South India. While expanding, the revenue decline in Pune indicates risks associated with geographic diversification and local market penetration.
Third Party Dependencies
Dependency on medical equipment OEMs for high-end radiology machines (MRI/CT) and reagent suppliers for pathology tests.
Technology Obsolescence Risk
The company mitigates technology risk by investing in new hub centers with modern diagnostic equipment, as evidenced by the performance of the Yelahanka hub.
Credit & Counterparty Risk
Not disclosed in available documents; diagnostic retail businesses generally have low counterparty risk due to cash-and-carry models.